E-LIB Suche - Ergebnisse für: Salles, G

1

Genomic Correlates of Radiosensitivity in Diffuse Large B C..:

Sarkar, R. R. ; Ma, J. ; Wijetunga, N. A....
Hematological Oncology. 41 (2023) S2 - p. 304-305 , 2023

Link: https://doi.org/10.1002/..

2

CNS radiotherapy as bridging prior to CAR T‐cell therapy fo..:

Cederquist, G. ; Hubbeling, H. ; Tringale, K....
Hematological Oncology. 41 (2023) S2 - p. 530-532 , 2023

Link: https://doi.org/10.1002/..

3

Efficacy of Subcutaneous Epcoritamab versus Axi‐cel in R/R ..:

Thieblemont, C. ; Fox, C. P. ; Wang, A....
Hematological Oncology. 41 (2023) S2 - p. 453-454 , 2023

Link: https://doi.org/10.1002/..

4

Patient‐ versus clinician‐reported symptoms in the POLARIX ..:

Thompson, C. A. ; Mehta‐Shah, N. ; Flowers, C....
Hematological Oncology. 41 (2023) S2 - p. 414-416 , 2023

Link: https://doi.org/10.1002/..

5

Genetic Alterations in Follicular Lymphoma Predict Response..:

Wijetunga, N. A. ; Lebow, E. ; Chan, A....
Hematological Oncology. 41 (2023) S2 - p. 291-292 , 2023

Link: https://doi.org/10.1002/..

6

PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R‐CHOP VERSUS R..:

Sehn, L. H ; Chamuleau, M. ; Lenz, G....
Hematological Oncology. 41 (2023) S2 - p. 849-850 , 2023

Link: https://doi.org/10.1002/..

7

Five‐year efficacy and safety of tafasitamab in patients wi..:

Duell, J. ; Abrisqueta, P. ; Andre, M....
Hematological Oncology. 41 (2023) S2 - p. 437-439 , 2023

Link: https://doi.org/10.1002/..

8

IBRUTINIB PLUS BR OR R‐CHOP IN PREVIOUSLY TREATED PATIENTS ..:

Nastoupil, L. J. ; Hess, G. ; Pavlovsky, M. A....
Hematological Oncology. 41 (2023) S2 - p. 872-874 , 2023

Link: https://doi.org/10.1002/..

9

Analysis of Real‐World Treatment Patterns and Outcomes Amon..:

Sehn, L. H. ; Wang, A. ; Yu, J....
Hematological Oncology. 41 (2023) S2 - p. 373-375 , 2023

Link: https://doi.org/10.1002/..

10

IMPACT OF RESPONSE TO SYSTEMIC BRIDGING THERAPY ON CLINICAL..:

Wills, B. ; Shouval, R. ; Flynn, J....
Hematological Oncology. 41 (2023) S2 - p. 199-201 , 2023

Link: https://doi.org/10.1002/..

11

PHASE 2 TRIAL OF NIVOLUMAB PLUS ADRIAMYCIN, VINBLASTINE, DA..:

Torka, P. ; Feldman, T. ; Savage, K....
Hematological Oncology. 41 (2023) S2 - p. 161-162 , 2023

Link: https://doi.org/10.1002/..

12

DYNAMICS OF RADIOMIC FEATURES FOLLOWING BRIDGING THERAPY DE..:

Imber, B. S. ; Silverman, E. A. ; Leithner, D....
Hematological Oncology. 41 (2023) S2 - p. 93-94 , 2023

Link: https://doi.org/10.1002/..

13

CHROMATIN ACCESSIBILITY PROFILING TO INCREASE DIAGNOSTIC AC..:

Julia, E. ; Mareschal, S. ; Chebel, A....
Hematological Oncology. 41 (2023) S2 - p. 192-193 , 2023

Link: https://doi.org/10.1002/..

14

Radiotherapy as an effective bridge for chemo‐refractory or..:

Cederquist, G. ; Tringale, K. ; Hajj, C....
Hematological Oncology. 41 (2023) S2 - p. 406-407 , 2023

Link: https://doi.org/10.1002/..

15

BRCA1/2 MUTATIONS IMPACT ON THE DEVELOPMENT OF BREAST IMPLA..:

Ghione, P. ; Arcila, M. ; Joseph, V....
Hematological Oncology. 41 (2023) S2 - p. 193-194 , 2023

Link: https://doi.org/10.1002/..